Regeneron: Q3 adjusted net profit falls 28%

(CercleFinance.com) - Regeneron Pharmaceuticals has reported Q3 2022 sales of 2.
93 billion dollars, down 15% y-o-y.

Meanwhile, adjusted earnings fell 28% to $1,270 million dollars, with adjusted EPS of $11.14, also down 28%.

"Our third quarter 2022 financial performance reflects strong commercial momentum across our business, highlighted by 11% revenue growth when excluding contributions from REGEN-COV and Ronapreve," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.

"We continued to drive shareholder value creation by realizing the benefits of our sustained investment in R&D, focusing on commercial execution, and allocating over $2.8 billion to share repurchases and business development initiatives in the first nine months of 2022," he added.


Copyright (c) 2022 CercleFinance.com. All rights reserved.